welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- login
FDA paves way for clinical trials of Sarepta’s Duchenne MD therapy SRP-5051
The U.S. Food and Drug Administration has taken a step that will allow Sarepta Therapeutics to start clinical trials of its Duchenne muscular dystrophy therapy SRP-5051.
That move was accepting the company’s Investigational New Drug application for SRP-5051. The therapy, known as a peptide phosphorodiamidate morpholino oligomer, is designed to treat those whose Duchenne MD stems from the exon 51 genetic mutation. They constitute the largest group of DMD patients — about 13 percent.
Genes are made up of dozens of components known as exons. A missing exon can lead to a gene mutation that generates a faulty protein, causing a disease.
rareRelated
-
Sarepta Therapeutics Statement on ICER Draft Evidence Report for Treatments for Duchenne Muscular DystrophySarepta Therapeutics, Inc., the leader...
-
An Open-Label Extension Study for Patients With Duchenne Muscular Dystrophy who Participated in Studies of SRP-5051The purpose of this extension study is t...
-
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Dose of SRP-5051 in Patients With Duc...The purpose of this study is to evaluate...
-
ICER Document Reviews Effectiveness of 3 Duchenne MD TherapiesThe Institute for Clinical and Economic ...
-
Duchenne Muscular Dystrophy: New Analysis Shows Drug Slows Down Respiratory DeclineDuchenne muscular dystrophy occurs in bo...
-
Wave Life Sciences Duchenne Muscular Dystrophy Clinical Trial Selected for FDA Complex Innovative Trial Designs Pilo...Wave Life Sciences Ltd., a biotechnology...
-
Insurers battle families over costly drug for fatal diseaseNolan and Jack Willis, twins from upstat...
